Halozyme’s stock reaches all-time high as subcutaneous drug delivery platform Enhanze drives incremental revenue growth.
Halozyme Therapeutics (HALO) shares climbed to a record high Friday, fueled by rising demand for its Enhanze drug delivery platform. The technology enables large-volume intravenous medications to be administered via subcutaneous injection, improving patient convenience and efficiency.
The surge follows recent earnings momentum and analyst upgrades, despite a 2029 patent expiration looming. Enhanze partnerships with major pharmaceutical firms have expanded, contributing to revenue growth and market optimism.
Trading volume spiked alongside the price rally, reflecting strong investor interest in the company’s growth trajectory and pipeline potential.